1. DOP39 Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study. (30th January 2023) Authors: Vermeire, S; Dignass, A; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Rubin, D T; Regueiro, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP43 Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patients. (30th January 2023) Authors: Dignass, A; Regueiro, M; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Vermeire, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North. (21st January 2022) Authors: Siegmund, B; Axelrad, J; Pondel, M; Osterman, M T; Ahmad, H A; Memaj, A; Regueiro, M; Armuzzi, A; Afzali, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i092 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOP45 Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn's disease: a post-hoc analysis of the ACCENT-2 trial. (25th January 2019) Authors: Vande Casteele, N; Papamichael, K; Jeyarajah, J; Osterman, M T; Cheifetz, A S Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S053 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P316 Ozanimod is an efficacious oral therapy after, 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North. (21st January 2022) Authors: Sands, B E; Dignass, A; Irving, P; Chiorean, M; Long, M; Eren, D; Ahmad, H A; Osterman, M T; Petersen, A; Elegbe, A; Ritter, T; Danese, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P390 Methotrexate is not superior to placebo in maintaining remission in patients with ulcerative colitis: results from the MERIT-UC study. (16th January 2018) Authors: Herfarth, H; Barnes, E L; Jackson, S; Valentine, J F; Hanson, J; Higgins, P D R; Isaacs, K L; Osterman, M T; Sands, B E; Lewis, J D Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S300 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P531 Efficacy of tofacitinib maintenance therapy for ulcerative colitis in remitting patients vs. patients with clinical response after 8 weeks of induction treatment. (25th January 2019) Authors: Reinisch, W; Osterman, M T; Doherty, G; Marren, A; Woodworth, D A; Lawendy, N; Kwok, K; Maller, E; Su, C Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S378 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P609 Impact of prior biologic exposure on durability of recaptured response to ozanimod during the True North open-label extension study. (30th January 2023) Authors: Colombel, J F; Rubin, D T; Vermeire, S; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Dignass, A; Regueiro, R Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i738 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P687 Durability of recaptured response to ozanimod during the True North open-label extension. (30th January 2023) Authors: Dignass, A; Regueiro, M; Colombel, J F; Jain, A; Canavan, J B; Wu, H; Lawlor, G; Osterman, M T; Vermeire, S; Rubin, D T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i817 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study. (30th January 2023) Authors: Vermeire, S; Colombel, J F; Rubin, D T; Ghosh, S; Jain, A; Lawlor, G; Osterman, M T; Wu, H; Canavan, J B; Chiorean, M V Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i844 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗